1 / 16

DISCUSSING CLINICAL TRIALS THE “S-A-F-E-R” APPROACH

DISCUSSING CLINICAL TRIALS THE “S-A-F-E-R” APPROACH. ROBERT BUCKMAN M.D.,PhD. PRINCESS MARGARET HOSPITAL UNIVERSITY OF TORONTO. DISCUSSING CLINICAL TRIALS S-A-F-E-R. Clinical trials appear to be: To the patient: Complicated, mysterious & scary To us:

nishan
Download Presentation

DISCUSSING CLINICAL TRIALS THE “S-A-F-E-R” APPROACH

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DISCUSSING CLINICAL TRIALSTHE “S-A-F-E-R” APPROACH ROBERT BUCKMANM.D.,PhD. PRINCESS MARGARET HOSPITAL UNIVERSITY OF TORONTO

  2. DISCUSSING CLINICAL TRIALS S-A-F-E-R Clinical trials appear to be: To the patient: Complicated, mysterious & scary To us: Straightforward and routine with recruitment being a major goal

  3. DISCUSSING CLINICAL TRIALS S-A-F-E-R It’s probably the umpteenth time we’ve said it…. But it’s the first time they’ve heard it (So how do we make it sound fresh?)

  4. DISCUSSING CLINICAL TRIALS S-A-F-E-R So what goes wrong? The “dark matter” of the interview We can easily make the dark matter “visible”

  5. DISCUSSING CLINICAL TRIALS S-A-F-E-R There’s a difference between PROCESS and OUTCOME: GOOD PROCESS REQUIRES RESPONSE TO CHANGE = SENSITIVITY = ACKNOWLEDGEMENT OF EMOTIONAL COMPONENT OF INTERACTION

  6. DISCUSSING CLINICAL TRIALS S-A-F-E-R S– SETTING & STARTING A – AGENDA F – FACTS at the same time as E – ENQUIRIES & EMOTIONS R – REINFORCERS & WRAP-UP

  7. DISCUSSING CLINICAL TRIALS S-A-F-E-R S – SETTING & STARTING • SETTING • GREETING • ENGAGING

  8. DISCUSSING CLINICAL TRIALS S-A-F-E-R A– AGENDA The agenda should be the first item on the agenda. “Tell them what you’re going to tell them”

  9. DISCUSSING CLINICAL TRIALS S-A-F-E-R F– FACTS • MAKE A CONSCIOUS EFFORT TO TRANSLATE MEDSPEAK INTO PLAIN LANGUAGE • GIVE INFO IN SMALL CHUNKS • CHECK RECEPTION • RESPOND TO EMOTIONS AS THEY ARISE

  10. DISCUSSING CLINICAL TRIALS S-A-F-E-R E – EMOTIONS & ENQUIRIES The three-step Empathic Response is the easiest way of acknowledging emotions

  11. DISCUSSING CLINICAL TRIALS S-A-F-E-R • ACKNOWLEDGING EMOTIONS: The Empathic Response • Identify the emotion (theirs or yours) • Identify the source of the emotion • Respond in a way that shows you have made that connection • You don’t have to feel the emotion yourself • You don’t have to agree with the viewpoint

  12. DISCUSSING CLINICAL TRIALS S-A-F-E-R • E-V-E The key to addressing emotionsEach response should be one of these • EXPLORING • VALIDATING • EMPATHIC

  13. DISCUSSING CLINICAL TRIALS S-A-F-E-R R – REINFORCERS & WRAP-UP REINFORCERS & WRAP-UP Reminders (or aides-memoire) can be JOTTED NOTES, BROCHURES, AN AUDIO TAPE (patient’s or yours) AND A FRIEND OR RELATIVE!

  14. DISCUSSING CLINICAL TRIALS S-A-F-E-R The bottom line: • Make it interactive • Translate Medspeak into plain language • Acknowledge all emotions (including uncertainty) • Don’t be afraid of saying “I don’t know” • Give reinforcement at end

  15. DISCUSSING CLINICAL TRIALS S-A-F-E-R The S-A-F-E-R way is the better way

  16. DISCUSSING CLINICAL TRIALS S-A-F-E-R

More Related